Company: BIAF
Filing Date: 2025-10-08
Form Type: PRE 14A
Source: 0001493152-25-017460
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-08
Form: PRE 14A
Chunk 1
---
inity Technologies, I am greatly encouraged by the growing adoption and use by physicians of our first test, CyPath ®Lung, a noninvasive test for lung cancer, and of the technological advancements that our team continues to make in its fight to address the urgent need for noninvasive, early-stage diagnosis.

Whether or not you plan to attend the Special Meeting, your vote matters.We encourage you to promptly vote your shares by proxy over the internet, via telephone or by mail.

Your trust in our team and belief in our technology are invaluable. On behalf of our Board of Directors, our executive leadership team, and our dedicated team of scientists and businesspeople, we extend our sincerest gratitude for your continued support of and investment in bioAffinity Technologies.

| Sincerely,                            |
| Maria Zannes                          |
| President and Chief Executive Officer |

<div align='center'>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

TO BE HELD ON NOVEMBER 11, 2025</div>

Notice is hereby given that bioAffinity Technologies, Inc. (the “ Company” or “ bioAffinity Technologies”) will host a special meeting of stockholders (the “ Special Meeting”) on Tuesday, November 11, 2025, at 8:00 a.m. Central Time. The Special Meeting will be held in person at the Company’s principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217. The Special Meeting is being held for the following purposes:

| (1) | To approve,                                                                                                                                
 pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 271,500 shares of our Common Stock, which includes (i) 223,831     
 shares of our Common Stock issuable upon the exercise of Common Stock purchase warrants issued in connection with our private placement    
 offering that closed on August 14, 2025 (the “August 2025 Common Warrants”), and (ii) 47,669 shares of                                     
 our Common Stock issuable upon the exercise of Common Stock purchase warrants issued in connection with our warrant inducement transaction 
 (the “Warrant Inducement”) that closed on August 14, 2025 (the “August 2025 Inducement Warrants”),                                         
 together the August 2025 Common Warrants and the Inducement Warrants, the “August 2025 Warrants”), respectively,                           
 that may be equal to or exceed 20%